REMARKS/ARGUMENTS

The Examiner is requiring restriction to one of the following groups:

Group I: Claims 1-16, 50-58 drawn to a method of selecting a patient.

Group II: Claims 17-32, drawn to a diagnostic method.

Group III: Claims 33-40, drawn to a method of identifying a target molecule.

Group IV: Claims 41-44, 46-49, 59-62 drawn to an MHC/antigen complex/kit.

Group V: Claims 45, drawn to a WT1 composition.

Applicants provisionally elect Group, Claims 1-16 and 50-58, drawn to a method of selecting a patient, and, as species, the HLA tetramer technique and the SEQ ID NO:2 peptide, with traverse on the grounds that no adequate reasons and/or examples have been provided to support a conclusion of patentable distinctiveness between the identified groups. Also, it has not been shown that a burden exists in searching the claims of the five groups.

Moreover, the M.P.E.P. § 803 states as follows:

> "If the search and examination of an entire application can be made without a serious burden, the Examiner must examine it on its merits, even though it includes claims to distinct or independent inventions."

Applicants respectfully submit that a search of all of the claims would not impose a serious burden on the Office.

Applicants have not elected a species for c) or d) because Group I does not include claims 41 and 43.

Accordingly, and for the reasons presented above, Applicants submit that the Office has failed to meet the burden necessary in order to sustain the Restriction Requirement. Withdrawal of the Restriction Requirement is respectfully requested.

Applicants respectfully submit that the above-identified application is now in

condition for examination on the merits, and early notice of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

James H. Knebel
Attorney of Record
Registration No. 22,630

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/07)